Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B
| Autor: | Kin Kong Li, Siu-Tong Law, Ming Kai Lee, Chun Keung Mok |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Time Factors Kidney medicine.disease_cause Gastroenterology Liver disease 0302 clinical medicine Liver Function Tests Risk Factors Telbivudine Hepatitis B e Antigens medicine.diagnostic_test Age Factors Entecavir Middle Aged Viral Load Treatment Outcome Female 030211 gastroenterology & hepatology Viral load Glomerular Filtration Rate medicine.drug Hepatitis B virus medicine.medical_specialty Guanine Renal function 03 medical and health sciences Hepatitis B Chronic Internal medicine medicine Humans Aged Retrospective Studies Hepatology business.industry Retrospective cohort study Recovery of Function medicine.disease 030104 developmental biology Drug Resistance Neoplasm DNA Viral Immunology business Liver function tests Biomarkers Thymidine |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 28:193-198 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000000519 |
| Popis: | BACKGROUND Data comparing the clinical outcomes of telbivudine (LdT) and entecavir (ETV) in elderly patients with chronic hepatitis B are limited. GOALS The aim of the present study was to compare the efficacy and renal safety of LdT and ETV in treatment-naive elderly (≥ 60 years) patients with chronic hepatitis B. METHODS A total of 33 patients treated with LdT were consecutively enrolled in the study. Each patient was matched on the basis of age, sex, and baseline hepatitis B virus (HBV) DNA levels with three to four randomly selected controls treated with ETV. RESULTS Clinical characteristics were comparable between the two groups. Higher cumulative HBeAg-seroconversion rates were observed in the LdT group than in the ETV group after 2 years (50 vs. 20%) and 3 years (50 vs. 26.67%) of treatment (all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|